Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a synthetic carrier of calcium sulphate (Stimulan®) releasing moxifloxacin

International Journal of Antimicrobial Agents

Volumn 33, Issue 4, 2009, Pages 354-359

  Kanellakopoulou, Kyriaki ^a   Galanopoulos, Ilias ^b   Soranoglou, Vassilios ^c   Tsaganos, Thomas ^a   Tziortzioti, Vassiliki ^a   Maris, Ioannis ^b   Papalois, Apostolos ^d   Giamarellou, Helen ^a   Giamarellos Bourboulis, Evangelos J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b G Gennimatas Hospital   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

^d ELPEN Pharmaceuticals   (Greece)

Author keywords

Calcium sulphate; Moxifloxacin; Osteomyelitis; Staphylococcus aureus

Indexed keywords

AMPHETAMINE; MOXIFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; CANCELLOUS BONE; COMPARATIVE STUDY; CONTROLLED STUDY; FIBROSIS; GIANT CELL; HISTOPATHOLOGY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BONE AND BONES; CALCIUM SULFATE; COLONY COUNT, MICROBIAL; DELAYED-ACTION PREPARATIONS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OSTEOMYELITIS; QUINOLINES; RABBITS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 61749092191     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.09.008     Document Type: Article

References (18)

1. Mader J.T., Shirtliff M.E., Bergquist S.C., and Calhoun J. Antimicrobial treatment of chronic osteomyelitis. Clin Orthop Relat Res 360 (1999) 47-65
2. Kanellakopoulou K., and Giamarellos-Bourboulis E.J. Carrier systems for the local delivery of antibiotics in bone infections. Drugs 59 (2000) 1223-1232
3. Gürsel I., Korkusuz F., Türesin F., Alaeddinoǧlu G., and Harici V. In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis. Biomaterials 22 (2001) 73-80
4. Kanellakopoulou K., Kolia M., Anastassiadis A., Korakis T., Giamarellos-Bourboulis E.J., Andreopoulos A., et al. Lactic acid polymers as biodegradable carriers of fluoroquinolones: an in vitro study. Antimicrob Agents Chemother 43 (1999) 714-716
5. Kanellakopoulou K., Thivaios G.C., Kolia M., Dontas I., Nakopoulou L., Dounis E., et al. Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin. Antimicrob Agents Chemother 52 (2008) 2335-2339
6. Dajcs J.J., Thibodeaux B.A., Marquart M.E., Girgis D.O., Traidej M., and O'Callaghan R.J. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob Agents Chemother 48 (2004) 1948-1952
7. Murakami K., Minamide W., Wada K., Nakamura E., Teraoka H., and Watanabe S. Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction. J Clin Microbiol 29 (1991) 2240-2244
8. Kanellakopoulou K., Galanakis N., Giamarellos-Bourboulis E.J., Rifiotis C., Papakostas K., Andreopoulos A., et al. Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a biodegradable system of lactic acid polymer releasing pefloxacin. J Antimicrob Chemother 46 (2000) 311-314
9. Norden C.W., and Kennedy E. Experimental osteomyelitis: a description of the model. J Infect Dis 122 (1990) 410-418
10. Kanellakopoulou K., Tsaganos T., Athanassiou K., Koutoukas P., Raftogiannis M., Skiadas I., et al. Comparative elution of moxifloxacin from Norian skeletal repair system and acrylic bone cement: an in vitro study. Int J Antimicrob Agents 28 (2006) 217-220
11. Thomas M.V., Puleo D.A., and Al-Sabbagh M. Calcium sulfate: a review. J Long Term Eff Med Implants 15 (2005) 599-607
12. Salgami E.V., Bowling F.L., Whitehouse R.W., and Boulton A.J. Use of tobramycin-impregnated calcium sulphate pellets in addition to oral antibiotics: an alternative treatment to minor amputation in a case of diabetic foot osteomyelitis. Diabetes Care 30 (2007) 181-182
13. Papagelopoulos P.J., Mavrogenis A.F., Tsiodras S., Vlastou C., Giamarellou H., and Soucacos P.N. Calcium sulphate delivery system with tobramycin for the treatment of chronic calcaneal osteomyelitis. J Int Med Res 34 (2006) 704-712
14. Turner T.M., Urban R.M., Hall D.J., Chye P.C., Segreti J., and Gitelis S. Local and systemic levels of tobramycin delivered from calcium sulfate bone graft substitute pellets. Clin Orthop Relat Res 437 (2005) 97-104
15. Gillespie W.J., and Allardyce R.A. Mechanisms of bone degradation in infection: a review of current hypotheses. Orthopedics 13 (1990) 407-410
16. Southwood L.L., Frisbie D.D., Kawcak C.E., Ghivizzani S.C., Evans C.H., and McIlwraith C.W. Evaluation of Ad-BMP-2 for enhancing fracture healing in an infected defect fracture rabbit model. J Orthop Res 22 (2004) 66-72
17. Metzler K., Hansen G.M., Hedlin P., Harding E., Drlica K., and Blondeau J.M. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 24 (2004) 161-167
18. Goldstein E.J., Citron D.M., Warren Y.A., Tyrrell K.L., and Rybak M.J. Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus. J Med Microbiol 57 (2008) 452-456